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Abstract
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is characterized by high constitutive vascular endothelial
growth factor A (VEGF-A) production that induces a specific vascular phenotype. We previously reported that this
phenotype may allow shedding of multicellular tumor fragments into the circulation, possibly contributing to the
development of metastasis. Disruption of this phenotype through inhibition of VEGF signaling may therefore result
in reduced shedding of tumor fragments and improved prognosis. To test this hypothesis, we investigated the
effect of neoadjuvant sorafenib treatment on tumor cluster shedding. PATIENTS AND METHODS: Patients with
renal cancer (n = 10, of which 8 have ccRCC) received sorafenib for 4 weeks before tumor nephrectomy. The
resection specimens were perfused, and the perfundate was examined for the presence of tumor clusters. Effects
of the treatment on the tumor morphology and overall survival were investigated (follow-up of 2 years) and
compared with a carefully matched control group. RESULTS: Neoadjuvant sorafenib treatment induced extensive
ischemic tumor necrosis and, as expected, destroyed the characteristic ccRCC vascular phenotype. In contrast to
the expectation, vital groups of tumor cells with high proliferation indices were detected in postsurgical renal
venous outflow in 75% of the cases. Overall survival of patients receiving neoadjuvant treatment was reduced
compared to a control group, matched with regard to prognostic parameters. CONCLUSIONS: These results
suggest that neoadjuvant sorafenib therapy for ccRCC does not prevent shedding of tumor fragments. Although
this is a nonrandomized study with a small patient group, our results suggest that neoadjuvant treatment may
worsen survival through as yet undefined mechanisms.
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Introduction
Although the molecular and cellular mechanisms that are involved in
metastatic spread of tumors are gradually being unraveled, much is
still poorly understood. Because metastatic disease is the leading cause
of death of patients with cancer, deciphering these mechanisms is of
extreme importance. The currently most popular paradigm is the seed
and soil hypothesis, put forward by Paget already in 1889 [1]. This
hypothesis states that solitary tumor cells that are shed from a tumor
(the seeds) can develop into clinically relevant lesions only in
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compatible tissues (the soil) where interactions with the specific tissue
microenvironment allow tumor outgrowth. Epithelial-to-mesenchymal
transition is nowadays seen as a key developmental program that needs
to be activated during cancer invasion and metastasis [2]. The
mesenchymal phenotype allows cells to migrate and spread through
surrounding extracellular matrix in a protease-dependent manner
before eventually invading into blood vessels and entering the
circulation [3,4].
We and others have proposed an alternative mechanism of
metastasis that is independent of epithelial-to-mesenchymal transi-
tion and does not require proteolytic degradation of the vessel wall
[5–7]. When investigating effects of constitutive overexpression of
vascular endothelial growth factor A (VEGF-A) on tumor histology
and biology, we found that this factor induced a highly metastatic
phenotype in melanoma xenografts. This phenotype could be
attributed to VEGF-A–induced development of a so-called micro-
nodular phenotype, which develops by budding of clusters of tumor
cells into dilated tumor vasculature. During this budding process, the
clusters become gradually covered with vessel wall elements as they
enter the blood vessel. We demonstrated that these clusters may
eventually enter the circulation and are ultimately caught in the lung
vasculature where they may grow out to pulmonary metastases [5].
In approximately 80% of clear cell renal cell carcinomas (ccRCCs),
the Von Hippel–Lindau (VHL) gene is mutated resulting in
nonfunctional Von Hippel Lindau protein (pVHL) [8]. As normal
pVHL is involved in the controlled degradation of hypoxia-inducible
factor 1 α, pVHL mutations result in accumulation of this
transcription factor and constitutive expression of its target gene
VEGF-A, also under normoxic conditions [9]. The majority of
VEGF-A–expressing ccRCCs present with a micronodular phenotype
[10]. We previously reported that ccRCC tumor cell clusters are often
located in the lumen of vessels from where they can enter the
circulation [11]. We observed a correlation between the occurrence of
these clusters in renal venous outflow and the presence of pulmonary
metastases suggesting that shedding of tumor cell clusters into the
circulation results in subsequent capture in the lung capillary bed,
followed by outgrowth.
The well-recognized importance of VEGF and PDGF signaling
pathways in ccRCC has provided a rationale for treating patients with
metastatic and progressive disease with tyrosine kinase inhibitors,
among which is sorafenib, a small-molecule inhibitor of VEGF
receptor and platelet derived growth factor receptor tyrosine kinases
and RAF kinase [12–14]. Although these therapies are indicated for
disseminated disease, patients with locally extensive RCC have also
been treated in phase II trials in a neoadjuvant setting with the aim to
reduce tumor size and downstage the tumors, facilitating complete
resection [15–17]. Limited histopathologic data show extensive
necrosis and fibrosis in the primary tumor on neoadjuvant treatment,
although a risk of fulminant angiogenic outgrowth during drug
holidays has been observed [18]. The destruction of the micronodular
phenotype of the tumor, which is a direct result of anti-VEGF
treatment, may also impinge on the metastatic potential of these
tumors, as has been suggested in previous preclinical studies [5].
Here, we investigated the effects of neoadjuvant sorafenib
treatment on the histopathology of the primary tumor, on shedding
of tumor cell clusters into the circulation, and on survival.
Materials and Methods
Patients
The study described here was a side study to Trial No.
NCT08602862 in which molecular imaging is performed on patients
with renal cell cancer after neoadjuvant sorafenib treatment. Part of
the data from the trial have been published before [19,20]. All
patients included in this study signed informed consent. Ten patients
were included in a period of 2 years. Eligible for sorafenib treatment,
followed by nephrectomy, were patients with RCC with a Karnoffsky
score N70% who did not receive prior chemotherapy, immunother-
apy, or radiation therapy. The decision to participate in the study was
not further influenced by clinical performance as Motzer scores were
calculated only at poststudy evaluation. Patient characteristics and
clinicopathologic parameters have been published before, and an
updated summary is given in Table 1, with more detailed information
on individual cases in Table 2 [19]. TNM staging was performed
according to the TNM classification, seventh edition. Tumors were
classified as ccRCC (n = 8), chromophobe RCC (n = 1), and papillary
RCC (n = 1). All tumors were pT3a, pT3b, or pT4 and G2 to G4.
Seven patients in the treatment group were in retrospect suspect for
having metastatic disease. Patients were treated for 4 weeks with
sorafenib (400 mg twice a day), and nephrectomy was performed 3
days after the last administration.
For survival analyses, we carefully composed a control group of
12 patients with ccRCC from our previous study who underwent
tumor nephrectomy without any neoadjuvant treatment [11]. This
group was matched to the treatment group with respect to TNM
staging. All patients in this control group had confirmed metastatic
disease at first presentation.
Perfusion of Nephrectomy Specimen and Analysis of Renal
Venous Blood
Renal outflow from tumor nephrectomies was examined essentially
as described [11]. In short, a balloon catheter was placed in the renal
artery, and the kidney was perfused with a controlled flow of 0.9%
NaCl using a peristaltic pump (Watson-Marlow, Rotterdam, The
Netherlands). Perfusion was continued at a rate of 30 ml/min until
Table 1. Patient Characteristics and Occurrence of Tumor Cell Clusters in Venous Outflow in Patients with Renal Carcinoma after Neoadjuvant Sorafenib Treatment and in Untreated Patients with
ccRCC.
n Median Age Sex Tumor Size BVI No. with Shed Tumor Clusters
Neoadjuvant 8 ccRCCs 58 (45-78) 70% M 9.4 cm (5-15) 7 of 8 (88%) 6 of 8 (75%)
2 Non-ccRCCs 57 (49-64) 50% M 6.1 cm (5.5-7.7) 0 of 2 (0%) 0 of 2 (0%)
Untreated * 14 ccRCCs 61 (43-70) 71% M 10.5 cm (6-16.5) 6 of 8 (75%) 10 of 14 (72%)
BVI, blood vessel invasion.
Difference between shedding of tumor cell clusters in neoadjuvant treated and untreated tumors is not different. Note that in the treated group, seven patients in retrospect were suspect of metastatic disease at first
presentation.
* Control group has been published in reference 10.
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the perfundate was clear. Typically, 500- to 750-ml perfundate was
collected. Outflow was filtered through a 75-μm mesh nylon sieve.
After washing the filter with 0.9% NaCl, the residue was collected,
concentrated by centrifugation (500g for 5 minutes), and fixed in
Unifix (Klinipath, Duiven, The Netherlands). Subsequently Agar-
Cyto blocks were prepared by carefully resuspending the fixed residue
in 2% liquid agarose (LE, analytical grade, Promega, Madison WI)
followed by standard paraffin embedding of the solidified agarose
blocks [21]. After this procedure, primary tumor tissue was processed
for standard diagnosis and immunohistochemical staining.
Immunohistochemistry
AgarCyto blocks and corresponding primary tumors were analyzed
by hematoxylin and eosin (H&E) staining and immunohistochem-
istry using antibodies against CD31 (Dako, Glostrup, Denmark) to
detect endothelial cells, collagen IV (Abcam, Cambridge, United
Kingdom) to detect vessel basement membrane, α-smooth muscle
actin (Sigma, Zwijndrecht, The Netherlands) to detect pericytes, and
carbonic anhydrase IX (M75, Dr. Oosterwijk) to detect tumor cells
[22]. Proliferating tumor cells were detected using an antibody against
Ki67 (clone sp6; Abcam). Inflammatory cells were detected using
antibodies against CD2 (Neomarkers, Fremont, CA) to detect T-
lymphocytes and myeloperoxidase (MPO; Neomarkers) to detect
granulocytes. Antibodies were visualized by appropriate biotin-
labeled secondary antibodies and avidin peroxidase (Vector Labora-
tories, Burlingame, CA), as previously described [23]. Primary tumors
were assessed for necrosis, blood vessel wall changes, carbonic
anhydrase-IX expression, micronodular phenotype, (micro)vascular
invasion, and inflammation. To minimize sampling errors, at least 10
paraffin blocks taken from different areas from each tumor were
analyzed. Ten untreated ccRCCs from our local pathology archive
were included as controls to assess extent of necrosis. Scoring for
micronodular phenotype, based on CD31 stainings, was performed
independently by two investigators (G.K.-U. and W.L.). To quantify
inflammatory cells, MPO and CD2 immunoreactivity was scored
independently by two pathologists (H.v.K. and G.K.-U.) as ranging
from 0 (no stained cells) to 3 (high density of positive cells). In case of
discordance, consensus was reached at a double-headed microscope.
Statistical Analysis
Relationships between neoadjuvant treatment and occurrence of
tumor material in renal outflow were analyzed in 2 × 2 contingency
tables using Fisher exact test (two sided) in IBM SPSS Statistics
version 20.0 (Chicago, IL). Median survival differences were tested in
GraphPad Prism version 5.03 (Graphpad Software Inc., San Diego,
CA) for significance using a Mantel-Cox test and were considered
significant at P b 0.05.
Results
Effects of Sorafenib Treatment on Primary Tumors
We first analyzed the effects of neoadjuvant sorafenib treatment on
the histopathology of RCCs. In our series, two renal tumors were of
the nonclear cell type. These tumor types do not constitutively
express VEGF-A and do not present with a micronodular vascular
phenotype. We included these tumors in the analyses to investigate if
lack of constitutive VEGF expression affects response to sorafenib.
Effects of sorafenib on the morphology of these tumors were minimal
(not shown). In contrast, sorafenib induced profound effects on the
ccRCCs; these all showed extensive areas of necrosis, although areas of
vital tumor tissue were still present (Figure 1, A and B). At
macroscopic cross-sectioning, abundant liquefactive necrosis was
observed more often than in historical control tumors that had been
processed similarly in our department (not shown).






























1 F 61.2 402 6.1 8.5 72 331 2.55 100 Yes pT3bG3 7.5 NS No 65+ None
2 M 67.7 483 8 7.7 NA 331 2.46 90-100 Yes pT3b/G2 6.0 + Yes 20 INF-α and sunitinib
3 M 60.7 464 8.8 5 67 240 2.43 90-100 Yes pT3b/G4 10.5 + Yes 18 Sunitinib
4 F 42.7 NA 8.2 9.6 NA 403 2.61 90-100 Yes pT2/G34 9.1 − No 37 Sunitinib
5 M 66.6 625 6.9 5.1 NA 178 2.51 90-100 Yes pT3b/G4 16.5 + Yes 13 INF-α
6 M 67.5 398 6.9 8.4 77 350 2.38 90-100 Yes pT3a/G3 12.0 NS No 27 INF-α and RIT
7 M 44.7 347 8.9 6 NA 265 2.35 90-100 Yes pT3b/G3 9.5 + Yes 66 Triple, RIT, and sunitinib
8 M 61.5 361 8.8 6.7 NA 281 2.32 90-100 Yes pT3b/G2 9.0 NS Yes 75 RIT, sunitinib
9 M 54.6 490 10 5.4 NA 209 2.52 90-100 Yes pT3a/G3 12.3 − Yes 78+ None
10 F 68.1 372 9.1 10.2 NA 235 2.58 90-100 Yes pT3a/G2 14.5 NS Yes 77+ RIT
11 M 69.3 889 5.6 8 78 437 2.88 90 Yes pT3b/G3 9.0 + Yes Lost to
follow-up
None
12 M 60.5 313 7.8 5.5 68 189 2.42 100 Yes pT3b/G3 14.0 NS Yes 56+ Sunitinib and temsirolimus
13 F 69.8 348 8.7 7.4 62 228 2.74 100 Yes pT3b/G3 9.0 NS Yes 64+ Pazopanib
14 M 46.2 291 9.8 9.5 67 240 2.38 90-100 Yes pT4/G4 8.5 + No 85+ Sunitinib, temsirolimus,
and pazopanib
Neoadjuvant sorafenib group
15 M 58.1 523 8.9 4.8 68 213 2.53 90-100 Yes pT3b/G3 13.0 NS No 35 RIT
16 M 77.8 500 7.9 9 72 274 2.56 100 Yes pT3b/G4 14.0 NS Yes 43 None
17 F 61.8 304 6.4 8.8 56 850 2.69 90 Yes pT3b/G2 6.5 + No 71+ None
18 M 47.1 427 7.7 12.2 78 489 2.68 90 Yes pT3b/G3 9.5 + No 7 Sorafenib
19 M 45.1 532 8.3 5.6 72 261 2.33 100 Yes pT3a/G34 6.5 + Yes 7 Sunitinib
20 M 57.5 360 7.2 9.1 64 309 3.32 80 Yes pT4/G4 15.0 + NA 10 Sunitinib
21 M 50.1 333 7.2 8.1 75 320 3.38 100 Yes pT3a/G4 5.5 − NA 7 Sorafenib
NA, not available; NS, not scored; LDH, lactace dehydrogenase; Hb, hemoglobin; Leuco, leukocytes; Neutro, neutrophils; Thrombo, thrombocytes; Calcium, corrected calcium; KPS, Karnofsky
performance score; INF-α, interferon-α; RIT, radioimmunotherapy; Triple, interferon-α plus interleukin-2 plus 5-fluorouracil.
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Histologically, the treated ccRCCs frequently showed prominent
edema and fibrinoid necrosis of the blood vessel walls (Figure 1, C
and D, arrows). Vessel lining by endothelial cells was often
discontinuous, with fragmentation and sometimes thrombus forma-
tion (Figure 1E, arrow). In central necrotic areas, remnants of
necrotic vessels were also observed (Figure 1A). Importantly, the
vascular changes induced by sorafenib were tumor specific as vessels in
normal renal tissue distant from the tumor showed a normal
appearance (not shown). Furthermore, the vasculature in vital tissue
in control (nontreated) ccRCC showed a regular endothelial lining
(Figure 1F).
In seven of eight ccRCCs, prominent blood vessel (micro)invasion
was observed (Table 1). None of the treated tumors showed a
micronodular phenotype (not shown), whereas this phenotype was
seen in 45% of the nontreated tumors [11].
In treated tumors, intratumoral lymphocyte densities were higher
than in control tumors (78% score 2 or higher vs 50% in control
tumors; Figure 2 and Table 3). A consistent observation was that very
high densities of lymphocytes were found associated with fibrovas-
cular structures (Figures 1B, arrows, and 2, A and B) and damaged
tumor vasculature (Figure 2, C and D), whereas nontreated ccRCC
showed some lymphocytic infiltrates mainly concentrated in the
tumor rim (Figure 2, E and F). Granulocyte counts as determined by
MPO staining were in general low (not shown).
Presence of Tumor Cell Groups in the Perfundate
In six of eight patients with ccRCC in the neoadjuvant group
(75%), small groups of CA-IX–positive tumor cells (3-15 cells) could
be detected in the filtered perfundate (a representative example is
shown in Figure 3A; see also Table 1). The cells were sometimes
loosely attached to each other and showed irregular cytoplasmic
extensions. All these groups contained proliferating tumor cells (Ki67
staining in Figure 3B). Association with endothelial cells or pericytes,
as demonstrated by CD31 or α-smooth muscle actin staining, was
not observed in any of the collected tumor cell groups (not shown).
This was in contrast to our previous study, where we found vessel
basement membranes and/or endothelial cell linings in 30% of tumor
cell clusters in untreated patients (see example in Figure 3C) [11].
Venous outflow material from the chromophobe and papillary RCC
did not contain tumor cells or clusters (Table 1).
Figure 1. Histologic analysis of effects of sorafenib treatment on primary tumor. Throughout the tumor, extensive areas of necrosis are
seen (H&E staining in A; note also necrotic remnants of blood vessels), whereas also areas of vital tumor can be observed,
interspersed with heavily inflamed fibrovascular structures (see H&E staining in B). A spectrum of tumoral blood vessel responses to
sorafenib treatment is seen, ranging from edema of the vessel wall (see arrows in C) to fibrinoid necrosis with endothelial cell
fragmentation, fibrin deposition, inflammatory cells (D, arrow), and obliteration (E, arrow). For comparison, F shows a nontreated
control tumor with the characteristic micronodular phenotype and undamaged blood vessels (arrow). Scale bar, 400 μm (in A); 200 μm
(in B and C); 100 μm (in D–F).
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Effect of Neoadjuvant Sorafenib Treatment on Survival
Because the control group was heterogeneous and to prevent bias,
the control group was narrowed down to match the treated group
with respect to disease stage and pathophysiological and clinical
parameters, ultimately resulting in 12 control patients and 7 patients
in the neoadjuvant group (see Table 2). Kaplan-Meier analysis of
patients in the neoadjuvant group revealed significantly poorer
overall survival than the control group (Figure 4) [11]. Even with
this small group, a significantly longer median survival was found in
the control group (66 months, range = 13-85 months, six patients
still alive), compared to the patients in the neoadjuvant sorafenib-
treated group (10 months, range = 7-71 months, one patient still
alive); P = .038. This resulted in a hazard ratio of 4.42 (confidence
interval = 1.09-16.81).
Discussion
We previously reported that in 33% of patients with ccRCC, tumor
cell clusters can be detected in renal venous outflow and that the
occurrence of these shed clusters correlates with the presence or
metachronous development of pulmonary metastasis [11]. The
presence of such tumor tissue fragments was also associated with
the micronodular phenotype that is characteristically found in tumors
with high VEGF-A expression [7,10]. Disruption of the VEGF-A–
induced micronodular phenotype by VEGFR2 inhibition in a mouse
model of human melanoma xenografts effectively inhibited pulmo-
nary metastasis [5]. In the present study, the effects of blocking
VEGF-A activity with sorafenib on shedding of tumor cell clusters
from human renal cell cancers was investigated.
Sorafenib treatment of papillary and chromophobic RCC (lacking
constitutive VEGF expression) was apparently ineffective: these
tumors contained minimal amounts of necrosis and hypoxia and
contained high vessel densities (data not shown). In contrast,
treatment of the ccRCCs destroyed the characteristic micronodular
phenotype and induced extensive necrosis, although large vital areas
were still present in all tumors. These areas homogeneously
expressed CA-IX [20], confirming the clear cell origin of these
tumors. The vascular endothelium in treated ccRCCs was damaged,
resulting in edema of the vessel walls, vasculitis, and fibrinoid
necrosis. Although on the basis of its tyrosine kinase inhibition
profile, sorafenib affects endothelial cells, we cannot completely
Figure 2. Inflammatory response in RCC after neoadjuvant sorafenib treatment. Shown are serial sections, stained with H&E (A) and the T-
lymphocyte marker CD2 (B). Note heavy infiltration of CD2-positive cells in B and perivascular lymphocytes in C and D (arrow). E and F
show H&E staining and CD2 staining, respectively, of serial sections of an untreated tumor (E). Lymphocyte infiltration is much less
profound and is mainly localized in the rim of the tumor (arrow in F). Scale bar, 400 μm (in A, B, E, and F); 100 μm (in C and D).
Table 3. Distribution of Lymphocytes Versus Granulocytes in ccRCC.
MPO CD2
Neoadjuvant Treated
Score 0 or 1 92% 22%
Score N1 7% 78%
Control group
Score 0 or 1 95% 50%
Score N1 5% 50%
Note that on sorafenib treatment, a lymphocytic infiltrate is induced.
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exclude additional direct proaptototic effects on tumor cells, as has
been suggested before [24].
In contrast to the initial expectation of lower shedding of tumor
cell groups, these were still observed in 75% of sorafenib-treated
patients. This was in line with the notion that seven of eight patients
had in retrospect suspected metastatic disease at the start of treatment.
In the subgroup of metastasized patients in the control group, a
similar percentage was seen (66%). We therefore conclude that
neoadjuvant sorafenib treatment does not have impact on the
shedding of tumor clusters. Of importance, most of the tumor cell
groups in the treatment group contained viable and even proliferating
cells. These cell groups were deprived of an endothelial cell lining, in
contrast to those in control patients where 30% of clusters were
associated with vessel wall elements.
The mechanism of tumor cluster shedding from treated
nonmicronodular tumors is not clear. All patients in whom tumor
cell groups were detected in the perfundate of the postnephrectomy
venous outflow presented with (micro)vascular invasion of tumor in
the vital tumor areas. Shed tumor cell groups may therefore represent
the vital remnants of these intravascularly located tumor fragments
that are shed from a destroyed tumor vasculature. Sorafenib-induced
destruction of the tumor vasculature and damaged vessel walls may
also facilitate direct entry of tumor cell clusters into the circulation.
Absence of vessel wall elements suggests that entrance of these cell
clusters into the circulation occurs through a mechanism that is
distinct from intravascular budding. Alternatively, the micronodular
phenotype, which had been initially present, may have been destroyed
by sorafenib by a direct toxic effect on endothelial cells, resulting in
denudation of the endothelial covering of the intravascular buds. Of
interest, a short course of antiangiogenic tyrosine kinases has been
shown to provoke a more invasive tumor phenotype in animal models
of cancer [25,26]. It remains to be established whether our
observations have a physiological link to these data.
We have previously examined the effects of anti-VEGF therapies
on angiogenic melanoma xenografts in mice and found a reduction in
the number of metastases in the lungs. This may be explained by the
fact that in that situation, the formation of a micronodular phenotype
is prevented, whereas in the current clinical study, established tumors
with such phenotype are subjected to treatment.
Our study suggests that neoadjuvant sorafenib treatment has a
negative impact on prognosis. However, we realize that there are
limitations to our study. As this was a side study to clinical trial,
designed to assess the effect of sorafenib on antibody-mediated
molecular imaging, the setup did not allow a randomized approach,
and clinicopathologic parameters could only be determined postne-
phrectomy. Furthermore, the number of included patients was
limited, and importantly, retrospective analysis revealed that most of
the patients in the treatment group had metastatic disease already at
the start of treatment. It would be of high importance to study the
effects of neoadjuvant treatment in patients without evidence of
metastatic disease. In addition, there were differences in treatment
regime at tumor recurrence that may have impacted on survival (see
Table 2). On the basis of our data, it is not possible to judge the
potential predictive value of Motzer scores for response to
neoadjuvant treatment. Yet, the highly significant negative effect
of neoadjuvant treatment on survival (hazard ratio = 4.4) in this
small patient population indicates that the use of sorafenib for
neoadjuvant treatment of ccRCCs, especially in patients with
metastatic disease, should be reconsidered and further studies are
needed on the basis of the ongoing trials. Whether this study should
be extended to larger groups of patients should be a serious matter of
debate given our results [25,26]. Of note, treatment with sunitinib, a
tyrosine kinase inhibitor with a similar target specificity as sorafenib,
in a phase II neoadjuvant setting did not reveal a negative effect [17].
Whether this is related to intrinsic differences between sorafenib and
sunitinib is unclear.
Another intrinsic limitation of our study is that the study design
did not allow pretreatment tumor sampling. However, because more
Figure 3. Characteristic example of a tumor cell group, collected
after perfusion of a ccRCC nephrectomy specimen (A and B).
Tumor origin of the cells is evidenced by immunohistochemical
staining for the ccRCC marker CA-IX (A). Note the high proliferation
index in this tumor cell cluster as evidenced by immunostaining for
the proliferation marker Ki67 (B). C shows an example of a laminin-
stained tumor cell cluster from the control group, illustrating that
this cluster is covered by wall elements. Scale bar, 50 μm.
Figure 4. Kaplan- Meier survival curve shows a significant
decrease in overall survival in the neoadjuvant treatment group.
P = .038; HR = 4.4.
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than 80% of ccRCCs show VHL mutations leading to high VEGF-A
levels and a micronodular phenotype, we consider it justified to
assume that the absence of this phenotype in the tumors in the
present study is the result of sorafenib treatment. A final potential
drawback is that sorafenib treatment was stopped 3 days before tumor
nephrectomy during which theoretically morphologic changes may
occur. This 3-day period is inevitable to prevent wound-healing
complications. It was recently described that discontinuation of
sunitinib treatment in patients with ccRCC in a neoadjuvant setting
may result in compensatory angiogenesis and a tumor rebound effect
[27]. In the sorafenib-treated tumors of the current study, no
indication for this phenomenon was found, but the time span
between the end of therapy and subsequent surgery might have been
too short. Neoadjuvant treatment of patients with ccRCC with the
anti-VEGF antibody bevacizumab does not appear to cause
compensatory angiogenesis, possibly due its circulation half-life of
approximately 21 days [27]. Although it would be interesting to
investigate the effects of this anti-VEGF antibody on tumor-cluster
shedding, such studies are not feasible because of expected wound-
healing complications during tumor nephrectomy.
A remarkable observation was the profound inflammatory
response in the vital tumor areas that was significantly higher than
in control tumors. How this inflammatory response contributes to
tumor biology is unclear. Sorafenib has been shown to inhibit
natural killer cell–mediated cytotoxicity in vitro, an effect that was
not seen with sunitinib [28]. Conversely, it has been shown that
sorafenib decreases the influx of immune-suppressing regulatory T
cells (Treg) in clinical samples of ccRCC, potentially leading to an
enhanced immune response and improved clinical outcome [19]. If
and how these counteractive effects have contributed to reduced
survival in the group of sorafenib-treated patients are not clear, and a
more detailed analysis of the lymphocytic infiltrates in treated versus
control tumors will be needed to evaluate the effects of these
therapies on antitumor immunity.
In conclusion, this study strongly suggests that neoadjuvant
sorafenib treatment of ccRCC destroys the characteristic VEGF-A–
induced micronodular phenotype of these tumors, causes specific
changes in tumor vasculature, and induces profound necrosis as well
as intratumoral inflammation. In contrast to the initial expectations,
neoadjuvant treatment did not reduce shedding of tumor fragments
into the circulation. Furthermore, neoadjuvant sorafenib treatment of
metastasized patients with ccRCC may worsen prognosis.
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